Reducing catheter-related bloodstream infections by DefenCath is strongly believed by CorMedix (CRMD), a biotech company focused on developing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the U.S and abroad. Today CorMedix announces the resubmission of DefenCath’s new drug application to the U.S. Food and Drug Administration (FDA). The review process will take 30 days from the day of submission.
Right now CRMD shares are trading above $4.50 after rising 13.50% on 250k volume. This year the stock is staying around $4.80 while struggling to break the $5 ceiling on the average volume of 166,272 shares. Unfortunately, it has been declining since March 1 of 2021.